PDF) P374 Non-alcoholic fatty liver disease in inflammatory bowel disease: Prevalence and risk factors
Collections | Cancer Gene Therapy
EULAR 2023 – Abstract archive
Media Kit 2020 2020
Media Kit 2020 2020
ECCO IBD by OCEAiN Organisation, Congress, Emotion, Association, iNnovation GmbH
European Crohn´s and Colitis Organisation - ECCO - Home
European Crohn´s and Colitis Organisation - ECCO - Volume 13, Issue 2
European Crohn´s and Colitis Organisation - ECCO - Home
PDF) DOP028 Second N-ECCO Consensus Statements on the European nursing roles in caring for patients with Crohn's disease or ulcerative colitis
European Crohn´s and Colitis Organisation - ECCO - Home
European Crohn´s and Colitis Organisation - ECCO - P489 Temporal trends of colectomy for ulcerative colitis in the multi-drug era; a population based cohort study.
European Crohn´s and Colitis Organisation - ECCO - Scientific Programme
European Crohn´s and Colitis Organisation - ECCO - 10th Congress of ECCO, Barcelona 2015
ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment
European Crohn´s and Colitis Organisation - ECCO - Scientific Programme
European Crohn´s and Colitis Organisation - ECCO - Statistics
European Crohn´s and Colitis Organisation - ECCO - Published ECCO Guidelines
European Crohn´s and Colitis Organisation - ECCO - Statistics
All abstracts for the ICOS Science Conference 2020 | ICOS
European Crohn´s and Colitis Organisation - ECCO - 9th Congress of ECCO, Copenhagen 2014
European Crohn´s and Colitis Organisation - ECCO - Home
PDF) 2nd N-ECCO Consensus Statements on the European Nursing Roles in Caring for Patients with Crohn's Disease or Ulcerative Colitis
European Crohn´s and Colitis Organisation - ECCO - P658 Evolution of disease phenotype, time to biological therapy and medium-, long-term colectomy rates in Ulcerative Colitis patients in Western Hungary – a population-based
European Crohn´s and Colitis Organisation - ECCO - P653 The changing epidemiology of IBD in the western world: a population-based study from Denmark
Vedolizumab as the first line of biologic therapy for ulcerative colitis and Crohn's disease – a systematic review with meta-analysis - Digestive and Liver Disease
Table of Contents page: European Journal of Cancer
